This brand name is authorized in Austria, Croatia, Cyprus, Ecuador, Estonia, Hong Kong SAR China, Lithuania, Malta, Poland, Romania, Singapore.
The drug STEROFUNDIN contains a combination of these active pharmaceutical ingredients (APIs):
1
|
UNII
451W47IQ8X - SODIUM CHLORIDE
|
Sodium chloride is the principle salt involved in maintaining the osmotic tension of blood and tissues. Changes in osmotic tension influence the movement of fluids and diffusion of salts in cellular tissue. |
|
2
|
UNII
660YQ98I10 - POTASSIUM CHLORIDE
|
Potassium plays a vital physiological role in maintenance of normal electrical excitability of nerve and muscle. It is also important in the genesis and correction of imbalances of acid-base metabolism. |
|
3
|
UNII
02F3473H9O - MAGNESIUM CHLORIDE
|
4
|
UNII
BBB2RG413E - CALCIUM CHLORATE DIHYDRATE
|
Calcium is the most abundant mineral in the body, and is an essential body electrolyte. Homeostasis is mainly regulated by the parathyroid hormone, by calcitonin, and by the activated form of vitamin D. Calcium is a structural component of bones and teeth. It is also required for blood clotting, neurotransmitter release, muscle contraction and normal heartbeat. |
|
5
|
UNII
4550K0SC9B - SODIUM ACETATE
|
6
|
UNII
J3TZF807X5 - MALIC ACID, L-
|
Below package inserts are available for further reading:
Document | Type | Information Source | |
---|---|---|---|
STEROFUNDIN Solution for infusion | MPI, EU: SmPC | Heads of Medicines Agencies (EU) |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
ATC Group | Classification | |
---|---|---|
B05BB01 | Electrolytes | B Blood and blood forming organs → B05 Blood substitutes and perfusion solutions → B05B I.V. solutions → B05BB Solutions affecting the electrolyte balance |
This drug has been assigned below unique identifiers within the countries it is being marketed:
Country | Identification scheme | Identifier(s) |
---|---|---|
EC | Agencia Nacional de Regulación, Control y Vigilancia Sanitaria | 2744-MEE-0517 |
EE | Ravimiamet | 1585470, 1585515, 1585526, 1585571, 1585582, 1585593, 1585605, 1585616, 1585627, 1766561, 1766572, 1766583, 1766594, 1766606, 1766617, 1766628, 1766639, 1766640 |
HK | Department of Health Drug Office | 56353 |
HR | Agencija za lijekove i medicinske proizvode | HR-H-201976335 |
LT | Valstybinė vaistų kontrolės tarnyba | 1066769, 1066770, 1066771, 1066772, 1070023, 1070024, 1070025, 1070026, 1070027, 1070028, 1070029, 1070030, 1070031, 1070032, 1070033, 1070034, 1070035, 1070036 |
MT | Medicines Authority | MA223/01701 |
PL | Rejestru Produktów Leczniczych | 100298261 |
RO | Agenția Națională a Medicamentului și a Dispozitivelor Medicale | W59928001, W59928002, W59928003, W59928004, W59928005, W59928006, W59928007, W59928008, W59928009, W59928010, W59928011, W59928012, W59928013, W59928014, W59928015, W59928016, W59928017, W59928018 |
SG | Health Sciences Authority | 13890P |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.